Literature DB >> 23615713

Stromal cell-derived factor-1 (SDF-1) enhances cells invasion by αvβ6 integrin-mediated signaling in ovarian cancer.

Baoyao Xue1, Weiguang Wu, Kan Huang, Tingting Xie, Xiaobo Xu, Hongju Zhang, Chunlei Qi, Junli Ge, Yuecheng Yu.   

Abstract

Ovarian carcinoma is a common gynecological malignancy and a great threat to health as a result of metastasis. The chemokine stromal-derived factor (SDF-1) plays multiple roles in tumor pathogenesis. However, the precise molecular mechanism underlying SDF-1-induced ovarian cancer cell invasion is still undefined. αvβ6 integrin is an important factor in tumor progression. Therefore, we speculate that SDF-1-enhanced ovarian cancer cell invasion is related to αvβ6 integrin-mediated signaling. After culturing with SDF-1, an obvious time- and dose-dependent increase in αvβ6 integrin was demonstrated. Furthermore, CXC receptor 4 (CXCR4) was responsible for SDF-1-induced αvβ6 integrin expression. Simultaneously, SDF-1 was found to dramatically enhance extracellular matrix degradation via urokinase-type plasminogen activator (uPA) expression and cell invasion by αvβ6 integrin expression; these reinforce failed to be increased when pretreatment was performed with the CXCR4 inhibitor AMD3100 or anti-αvβ6 integrin antibody, respectively. In addition, αvβ6 integrin induced the phosphorylation of p38 MAPK and PI3 K/Akt, contributing to the up-regulation of uPA, as treatment with the specific inhibitor for p38 mitogen-activated protein kinases (MAPK) (SB203580) or phosphatidylinositol 3-kinase (PI3 K)/Akt (LY294002) strikingly abrogated uPA expression. Taken together, these results demonstrated that SDF-1 enhanced ovarian cancer cell invasion through αvβ6 integrin-mediated uPA expression via the p38 MAPK and PI3 K/Akt pathway. Consequently, our findings will provide a new explanation about how SDF-1 aggravates the pathogenesis of ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23615713     DOI: 10.1007/s11010-013-1671-1

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  31 in total

Review 1.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

Review 2.  Alphavbeta6 integrin in wound healing and cancer of the oral cavity.

Authors:  G J Thomas; M L Nyström; J F Marshall
Journal:  J Oral Pathol Med       Date:  2006-01       Impact factor: 4.253

3.  The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases.

Authors:  Roderick J Phillips; Marie D Burdick; Marin Lutz; John A Belperio; Michael P Keane; Robert M Strieter
Journal:  Am J Respir Crit Care Med       Date:  2003-03-05       Impact factor: 21.405

Review 4.  Stromal effects on mammary gland development and breast cancer.

Authors:  Bryony S Wiseman; Zena Werb
Journal:  Science       Date:  2002-05-10       Impact factor: 47.728

5.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

6.  Expression and activation of alpha v beta 3 integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells.

Authors:  Yan-Xi Sun; Ming Fang; Jianhua Wang; Carlton R Cooper; Kenneth J Pienta; Russell S Taichman
Journal:  Prostate       Date:  2007-01-01       Impact factor: 4.104

7.  TGF-β and αvβ6 integrin act in a common pathway to suppress pancreatic cancer progression.

Authors:  Aram F Hezel; Vikram Deshpande; Stephanie M Zimmerman; Gianmarco Contino; Brinda Alagesan; Michael R O'Dell; Lee B Rivera; Jay Harper; Scott Lonning; Rolf A Brekken; Nabeel Bardeesy
Journal:  Cancer Res       Date:  2012-07-11       Impact factor: 12.701

8.  Lysophosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q).

Authors:  Ming Yan Xu; Joanne Porte; Alan J Knox; Paul H Weinreb; Toby M Maher; Shelia M Violette; Robin J McAnulty; Dean Sheppard; Gisli Jenkins
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

9.  Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4.

Authors:  Zhongxing Liang; Tao Wu; Hong Lou; Xiwen Yu; Russell S Taichman; Stephen K Lau; Shuming Nie; Jay Umbreit; Hyunsuk Shim
Journal:  Cancer Res       Date:  2004-06-15       Impact factor: 12.701

10.  MAPK and JNK transduction pathways can phosphorylate Sp1 to activate the uPA minimal promoter element and endogenous gene transcription.

Authors:  Elisa Benasciutti; Gilles Pagès; Olga Kenzior; William Folk; Francesco Blasi; Massimo P Crippa
Journal:  Blood       Date:  2004-03-18       Impact factor: 22.113

View more
  15 in total

Review 1.  Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis.

Authors:  Won-Tak Choi; Yilei Yang; Yan Xu; Jing An
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

2.  miR-448 negatively regulates ovarian cancer cell growth and metastasis by targeting CXCL12.

Authors:  Y Lv; Y Lei; Y Hu; W Ding; C Zhang; C Fang
Journal:  Clin Transl Oncol       Date:  2015-06-24       Impact factor: 3.405

Review 3.  CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks.

Authors:  F Guo; Y Wang; J Liu; S C Mok; F Xue; W Zhang
Journal:  Oncogene       Date:  2015-05-11       Impact factor: 9.867

Review 4.  Mechanisms and Targets Involved in Dissemination of Ovarian Cancer.

Authors:  Ulrich H Weidle; Fabian Birzele; Gwendlyn Kollmorgen; Rüdiger Rueger
Journal:  Cancer Genomics Proteomics       Date:  2016 11-12       Impact factor: 4.069

Review 5.  Slit/Robo pathway: a promising therapeutic target for cancer.

Authors:  Rishi K Gara; Sonam Kumari; Aditya Ganju; Murali M Yallapu; Meena Jaggi; Subhash C Chauhan
Journal:  Drug Discov Today       Date:  2014-09-20       Impact factor: 7.851

Review 6.  The intricate role of CXCR4 in cancer.

Authors:  Samit Chatterjee; Babak Behnam Azad; Sridhar Nimmagadda
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

7.  Integrin β6 acts as an unfavorable prognostic indicator and promotes cellular malignant behaviors via ERK-ETS1 pathway in pancreatic ductal adenocarcinoma (PDAC).

Authors:  Zequn Li; Pengfei Lin; Chao Gao; Cheng Peng; Song Liu; Huijie Gao; Ben Wang; Jiayong Wang; Jun Niu; Weibo Niu
Journal:  Tumour Biol       Date:  2015-11-07

Review 8.  Chemokine receptors in epithelial ovarian cancer.

Authors:  Goda G Muralidhar; Maria V Barbolina
Journal:  Int J Mol Sci       Date:  2013-12-31       Impact factor: 5.923

Review 9.  Novel strategies for the treatment of chondrosarcomas: targeting integrins.

Authors:  Jui-Chieh Chen; Yi-Chin Fong; Chih-Hsin Tang
Journal:  Biomed Res Int       Date:  2013-12-30       Impact factor: 3.411

10.  The influence of lentivirus-mediated CXCR4 RNA interference on hepatic metastasis of colorectal cancer.

Authors:  Tian-Bao Wang; Bao-Guang Hu; Da-Wei Liu; Han-Ping Shi; Wen-Guang Dong
Journal:  Int J Oncol       Date:  2014-03-19       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.